People who have at least one copy of the following CFTR gene mutations are eligible to take Alyftrek (vanzacaftor/tezacaftor/deutivacaftor):

3195del6	G149R	L1065P	R516G
3199del6	G91R	M1101R	R560S
A559T	H199R	P99L	R560T
A559V	H609R	Q1100P	T604I
A561E	I1234Vdel6aa	Q452P	V520F
A613T	I1398S	R1066C	Y569C
A72D	I506T	R1066L	Y913C
D513G	L102R	R1066M	

People who have at least one copy of the following CFTR gene mutations are eligible to take Alyftrek and Trikafta (elexacaftor/tezacaftor/ivacaftor):

[table continued on page 2]:

1341G→A	A107G	E116K	F587I	G576A;R668C†
1507_1515del9	A120T	E116Q	G1047R	G622D
1898+3A→G	A234D	E193K	G1061R	G628R
2183A→G	A309D	E292K	G1069R	G85E
2752-26A→G	A349V	E403D	G1123R	G970D
2789+ 2insA	A455E	E474K	G1244E	G970S
2789+5G→A	A46D	E56K	G1247R	H1054D
296+28A→G	A554E	E588V	G1249R	H1085P
3041-15T→G	A62P	E60K	G126D	H1085R
3141del9	C491R	E822K	G1349D	H1375P
3272-26A→G	D110E	E831X	G178E	H139R
3600G→A	D110H	E92K	G178R	H199Y
3849+10kbC→T	D1152H	F1016S	G194R	H620P
3849+40A→G	D1270N	F1052V	G194V	H620Q
3849+4A→G	D1445N	F1074L	G27E	H939R
3850-3T→G	D192G	F1099L	G27R	H939R;H949L
4005+2T→C	D443Y	F1107L	G314E	I1027T
546insCTA	D443Y;G576A;R668C	F191V	G424S	I105N
5T;TG12	D565G	F200I	G463V	I1139V
5T;TG13	D579G	F311del	G480C	I125T
621+3A→G	D614G	F311L	G480S	I1269N
711+3A→G	D836Y	F508C	G551A	I1366N
A1006E	D924N	F508C;S1251N†	G551D	I148N
A1067P	D979V	F508del*	G551S	I148T
A1067T	D993Y	F575Y	G576A	I175V

People who have at least one copy of the following CFTR gene mutations are eligible to take Alyftrek and Trikafta:

[table continued from page 1]:

I331N	M1101K	R1066H	R74Q	T1036N
I336K	M1137V	R1070Q	R74W	T1053I
I502T	M150K	R1070W	R74W;D1270N†	T1086I
I506L	M152V	R1162L	R74W;V201M;D1270N†	T1246I
I556V	M265R	R117C	R74W;V201M†	T1299I
I601F	M952I	R117C;G576A;R668C	R751L	T338I
I618T	M952T	R117G	R75L	T351I
I807M	N1088D	R117H	R75Q	V1153E
I980K	N1303I	R117L	R792G	V1240G
K1060T	N1303K	R117P	R933G	V1293G
K162E	N186K	R1283M	S1045Y	V201M
K464E	N187K	R1283S	S108F	V232D
L1011S	N418S	R170H	S1118F	V392G
L1077P	P140S	R258G	S1159F	V456A
L1324P	P205S	R297Q	S1159P	V456F
L1335P	P499A	R31C	S1235R	V562I
L137P	P574H	R31L	S1251N	V603F
L1480P	P5L	R334L	S1255P	V754M
L15P	P67L	R334Q	S13F	W1098C
L165S	P750L	R347H	S341P	W1282R
L206W	Q1291R	R347L	S364P	W361R
L320V	Q1313K	R347P	S492F	Y1014C
L333F	Q237E	R352Q	S549I	Y1032C
L333H	Q237H	R352W	S549N	Y109N
L346P	Q359R	R516S	S549R	Y161D
L441P	Q372H	R553Q	S589N	Y161S
L453S	Q493R	R555G	S737F	Y301C
L619S	Q552P	R668C	S912L	Y563N
L967S	Q98R	R668C†	S945L	
L997F	R1048G	R709Q	S977F	

*F508del is a responsive CFTR mutation based on both clinical and in vitro data.

†Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.

Source: U.S. Food and Drug Administration